Formulation And Evaluation Of Lornoxicam Co – Crystal Tablet With Ibuprofrn Treatment Of Arthritis
Keywords:
Lornoxicam, Co-crystal, Solvent evaporation, Trimesic acid, Solubility enhancement, Controlled drug release, Non-Fickian diffusion, Sodium carbonateAbstract
This study investigates the use of the solvent evaporation technique for developing co-crystals of Lornoxicam with Trimesic Acid (TA) to improve solubility, flowability, and drug release characteristics. Among the methods explored, solvent evaporation proved to be the most effective for producing co-crystals with enhanced physicochemical properties. Saturation solubility studies showed that while pure Lornoxicam had a solubility of 5.98 mg/mL, the co-crystal formulation LXM-TA CFIII achieved a 13.52-fold increase, indicating significant improvement. Crystals obtained through the solvent drop method demonstrated superior flow properties compared to those prepared via co-grinding or solvent evaporation. In vitro drug release studies revealed that pure Lornoxicam released 86.3% of its content within 360 minutes, whereas LXM-TA CFIII released up to 98.2%. This formulation followed a non-Fickian release mechanism, confirmed by a high regression value (R² = 0.999) and a release exponent (n = 0.793), indicating both diffusion and erosion-based release. In vivo testing on male albino mice showed that LXM-TA CFIII, administered at doses of 10, 20, and 30 mg/kg, led to dose-dependent improvements in protection and faster recovery times, with the 10 mg/kg dose offering the highest protective efficacy. Additionally, the role of electrolytes in matrix tablet formulation was evaluated. Sodium carbonate was identified as the most effective retardant for drug release. Formulation F14, containing an optimal level of sodium carbonate, demonstrated sustained drug release over 12 hours, supporting its use in twice-daily dosing. Overall, this research confirms the potential of cocrystallization and matrix modification techniques to enhance the bioavailability and therapeutic performance of poorly soluble drugs like Lornoxicam.
Downloads
References
Aakeröy, C. B., & Salmon, D. J. (2005). Building co-crystals with molecular sense and supramolecular sensibility. Crystal Engineering Communications, 7(72), 439–448. https://doi.org/10.1039/b500870m
Schultheiss, N., & Newman, A. (2009). Pharmaceutical cocrystals and their physicochemical properties. Crystal Growth & Design, 9(6), 2950–2967. https://doi.org/10.1021/cg900129f
Braga, D., Maini, L., & Grepioni, F. (2013). Mechanochemical preparation of co- crystals. Chemical Society Reviews, 42(18), 7638–7648. https://doi.org/10.1039/C3CS60122A
Shan, N., & Zaworotko, M. J. (2008). The role of cocrystals in pharmaceutical science.
Drug Discovery Today, 13(9–10), 440–446. https://doi.org/10.1016/j.drudis.2008.03.004
Bhardwaj, R. M., et al. (2013). Stability and dissolution of co-crystals in comparison to polymorphs and salts: A brief review. Pharmaceutical Research, 30(1), 78–95. https://doi.org/10.1007/s11095-012-0852-0
Qiao, N., et al. (2011). Pharmaceutical cocrystals: An overview. International Journal of Pharmaceutics, 419(1–2), 1–11. https://doi.org/10.1016/j.ijpharm.2011.07.037
Tanaka, N., et al. (2012). Cocrystal approach for solubility enhancement of poorly watersoluble drugs. International Journal of Pharmaceutics, 437(1–2), 152–160. https://doi.org/10.1016/j.ijpharm.2012.08.037
Vishweshwar, P., McMahon, J. A., Bis, J. A., & Zaworotko, M. J. (2006).
Pharmaceutical co-crystals. Journal of Pharmaceutical Sciences, 95(3), 499–516. https://doi.org/10.1002/jps.20578
Kumar, S., & Nanda, A. (2017). Solubility enhancement of lornoxicam by pharmaceutical cocrystals: Design, preparation and characterization. Pharmaceutics, 9(2), 38. https://doi.org/10.3390/pharmaceutics9020038
Jamroz, W., Kurek, M., & Szafraniec-Szczęsny, J. (2019). Co-crystal formation in drug formulation. Current Pharmaceutical Design, 25(30), 3305–3320.
https://doi.org/10.2174/1381612825666190625102826
Allen, L. V. (2017). Basic concepts of formulation design: The development of solid dosage forms. International Journal of Pharmaceutical Compounding, 21(1), 4–13.
Palanisamy, P., et al. (2020). Development of lornoxicam-loaded solid dispersions for improved solubility and anti-arthritic activity. Drug Development and Industrial Pharmacy, 46(5), 708–719. https://doi.org/10.1080/03639045.2020.1736632
Ashutosh, D., & Mandal, S. (2021). A co-crystallization approach to enhance bioavailability and solubility of nonsteroidal anti-inflammatory drugs. Journal of Drug
Delivery Science and Technology, 66, 102751. https://doi.org/10.1016/j.jddst.2021.102751
Schoenemann, H., et al. (2018). Formulation challenges for fixed-dose combination tablets: Case studies. International Journal of Pharmaceutics, 536(1), 56–64. https://doi.org/10.1016/j.ijpharm.2017.10.011
Malfait, A. M., Schnitzer, T. J., & Miller, R. E. (2017). The role of nerve growth factor in arthritis pain: Progress and therapeutic implications. Arthritis Research & Therapy, 19(1), 1–8. https://doi.org/10.1186/s13075-017-1348-6
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
